NCT03671044 - A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | Biotech Hunter

Enrollment

657

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Nanosomal Docetaxel Lipid Suspension (75 mg/m2)

Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.

DRUG

Nanosomal Docetaxel Lipid Suspension (100 mg/m2)

Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.

DRUG

Taxotere® (100 mg/m2)

Docetaxel Injection Concentrate; 20 mg/0.5 mL

Trial Locations (4)

RECRUITING

Columbus Regional Research Institute, LLC, Columbus

RECRUITING

Gabrail Cancer Center, Canton

RECRUITING

Cox Medical Center, Springfield

RECRUITING

Kailash Cancer Hospital & Research Centre, Vadodara